Filing Details

Accession Number:
0001209191-19-011362
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-19 19:38:58
Reporting Period:
2019-02-14
Accepted Time:
2019-02-19 19:38:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1131324 Genomic Health Inc GHDX Services-Medical Laboratories (8071) 770552594
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1333482 J Kimberly Popovits 301 Penobscot Dr.
Redwood City CA 94063
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-14 47,900 $17.18 164,882 No 4 M Indirect Held by the Popovits 2010 Trust
Common Stock Disposition 2019-02-14 34,000 $81.46 130,882 No 4 S Indirect Held by the Popovits 2010 Trust
Common Stock Disposition 2019-02-14 13,900 $82.30 116,982 No 4 S Indirect Held by the Popovits 2010 Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect Held by the Popovits 2010 Trust
No 4 S Indirect Held by the Popovits 2010 Trust
No 4 S Indirect Held by the Popovits 2010 Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2019-02-14 47,900 $0.00 47,900 $17.18
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-02-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 68,028 Direct
Common Stock 12,298 Indirect Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits
Footnotes
  1. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 17, 2018.
  2. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
  3. Represents weighted average sale price. Actual sale prices ranged from $81.05 to $82.045.
  4. Represents weighted average sale price. Actual sale prices ranged from $82.06 to $82.83.
  5. Includes an aggregate of 62,164 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
  6. The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.